# Delix Therapeutics

reported positive efficacy data for its lead non-hallucinogenic psychoplastogen DLX-001 (zalsupindole) in October 2025, alongside FDA clearance of a Phase II trial design featuring at-home administration rather than clinic-based supervised dosing.

Source: https://en.bioecon.ru/companies/delix-therapeutics/
Updated: 2026-07-04

- Country: United States

## Technologies

- [Psychedelic medicine & neuropsychiatric biologics](https://en.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/)